The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani

BACKGROUND: New drugs are needed for leishmaniasis because current treatments such as pentavalent antimonials are toxic and require prolonged administration, leading to poor patient compliance. Ibrutinib is an anticancer drug known to modulate T-helper type 1 (Th1)/Th2 responses and has the potentia...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Infect Dis
Autors principals: Varikuti, Sanjay, Volpedo, Greta, Saljoughian, Noushin, Hamza, Omar M, Halsey, Gregory, Ryan, Nathan M, Sedmak, Bren E, Seidler, Gabriella R, Papenfuss, Tracey L, Oghumu, Steve, Satoskar, Abhay R
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Major Articles and Brief Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784510/
https://ncbi.nlm.nih.gov/pubmed/30239895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jiy552
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars